Ladenburg Thalmann Initiates Equity Research Analyst Coverage on Aeolus
August 29 2011 - 2:33PM
Marketwired
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (PINKSHEETS: AOLS) today
announced that Ladenburg Thalmann & Co. Inc. initiated equity
research coverage on the Company with a "Buy" recommendation and a
12-month price target of $1.25 per share. The new report, issued on
August 24, 2011 was authored by Kevin DeGeeter, Director, Equity
Research Analyst.
To request a copy of the report, please contact Kevin DeGeeter.
His contact information can be found at
http://www.aeoluspharma.com/Investors/Analysts.
Neither Aeolus Pharmaceuticals, Inc., nor any of its affiliates,
endorse, confirm or adopt the contents of the Ladenburg Thalmann
equity research report nor accept any responsibility for its
accuracy, which is the sole responsibility of its author. Aeolus
undertakes no obligation to revise or update this Report to reflect
events or circumstances after its issuance or otherwise. The reader
should review all disclaimers contained in this Report. Aeolus is
subject to significant risks, and a discussion of such risks can be
found by reviewing Aeolus' SEC filings including Annual and
Quarterly Reports as filed on Form 10-K and Form 10-Q
respectively.
About AEOL 10150
AEOL 10150 is a broad-spectrum catalytic antioxidant
specifically designed to neutralize reactive oxygen and nitrogen
species. The neutralization of these species reduces oxidative
stress, inflammation, and subsequent tissue damage-signaling
cascades resulting from radiation exposure. AEOL 10150 could have a
profound beneficial impact on people who have been exposed, or are
about to be exposed, to high-doses of radiation in the treatment of
oncology.
AEOL 10150 has already performed well in preclinical and
non-clinical studies, was well-tolerated in two human clinical
trials, and has demonstrated statistically significant survival
efficacy in an acute radiation-induced lung injury model. The
Company believes it could have a profound beneficial impact on
people who have been exposed, or are about to be exposed, to
high-doses of radiation, whether from cancer therapy or a nuclear
event.
About Aeolus Pharmaceuticals
Aeolus Pharmaceuticals is developing a new class of catalytic
antioxidant compounds that protects healthy tissue from the
damaging effects of radiation. Its first compound, AEOL 10150, is
being developed for oncology indications, where it is used in
combination with radiation therapy. It is also being developed,
with funding by the US Government, as a medical countermeasure
against chemical and radiological weapons, where its initial target
indications are as a protective agent against the effects of acute
radiation syndrome and delayed effects of acute radiation exposure.
Aeolus' strategy is to leverage the substantial investment in
toxicology, manufacturing, and preclinical and clinical studies
made by US Government agencies in AEOL 10150, including the
contract with BARDA valued, with options, at up to $118 million, to
efficiently develop the compound for use in oncology.
Forward-Looking Statements
The statements in this press release that are not purely
statements of historical fact are forward-looking statements. Such
statements include, but are not limited to, those relating to
Aeolus' product candidates, as well as its proprietary technologies
and research programs. Such forward-looking statements involve
known and unknown risks, uncertainties and other factors that may
cause Aeolus' actual results to be materially different from
historical results or from any results expressed or implied by such
forward-looking statements. Important factors that could cause
results to differ include risks associated with uncertainties of
progress and timing of clinical trials, scientific research and
product development activities, difficulties or delays in
development, testing, obtaining regulatory approval, the need to
obtain funding for pre-clinical and clinical trials and operations,
the scope and validity of intellectual property protection for
Aeolus' product candidates, proprietary technologies and their
uses, and competition from other biopharmaceutical companies.
Certain of these factors and others are more fully described in
Aeolus' filings with the Securities and Exchange Commission,
including, but not limited to, Aeolus' amended Annual Report on
Form 10-K/A for the year ended September 30, 2010. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof.
Contact: Russell Skibsted (949) 481-9825
Aeolus Pharmaceuticals (CE) (USOTC:AOLS)
Historical Stock Chart
From Sep 2024 to Oct 2024
Aeolus Pharmaceuticals (CE) (USOTC:AOLS)
Historical Stock Chart
From Oct 2023 to Oct 2024